Cure8 research brief
People with suspected or known IBD and their clinicians want accurate, noninvasive tests to detect inflammation. This review suggests NGAL may be sensitive for identifying IBD but existing data are limited and uncertain, so it’s not ready to replace current tests like fecal calprotectin.
Clinicians evaluating diagnostic tests for IBD, laboratory scientists and researchers studying IBD biomarkers, and patients interested in emerging noninvasive tests for intestinal inflammation.
This BMC Gastroenterology article reports a systematic review and bivariate diagnostic meta-analysis evaluating neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic biomarker for IBD, compared to fecal calprotectin (FC), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).
The pooled analysis found NGAL had a high pooled sensitivity (about 91%) but moderate specificity (about 76%); however the NGAL estimate was imprecise and underpowered because only a small number of NGAL records and complete four-cell data were available.
The authors conclude NGAL may show promise for detecting IBD but the current evidence is preliminary, heterogeneous, and insufficient to recommend NGAL as a replacement for fecal calprotectin or as a stand-alone diagnostic test. They call for larger prospective studies with standardized thresholds, sample types, and reference standards.
This brief is grounded in the article abstract provided by the journal (structured content depth: abstract) and does not represent independent review of the full study beyond that abstract.
The NGAL pooled estimate is based on very few complete diagnostic records and showed high heterogeneity. The review used endoscopy and/or histopathology as reference standards; authors emphasize need for larger, standardized prospective studies. Because the source material is the article abstract, details beyond the abstract were not assessed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Knowing which symptoms and non-invasive biomarkers most strongly associate with UC can help patients and clinicians decide who should be prioritized for diagnostic endoscopy and for monitoring disease activity.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Standardized intestinal ultrasound scoring could help non-invasively monitor Crohn’s disease activity and reduce reliance on colonoscopy for some assessments. A high-sensitivity IUS score may be useful to rule out...
